Superior safety and equipotent efficacy of paracetamol versus ibuprofen for closure of patent ductus arteriosus: An integrative review (2015–2025)

Authors

  • Carlos María Gómez Facultad de Ciencias Médicas, Universidad Privada del Este, filial Presidente Franco, Paraguay Autor/a
  • Diana Mabel Ávila Ojeda Servicio de Pediatría, Hospital General de Itapúa, Paraguay Autor/a
  • Ruth Leiva Servicio de Pediatría, Hospital General de Itapúa, Paraguay Autor/a
  • Tania Montenegro Servicio de Pediatría, Hospital General de Itapúa, Paraguay Autor/a
  • Shirley Michelle Huang Liao Servicio de Pediatría, Hospital General de Itapúa, Paraguay Autor/a
  • Denise Muñoz Unidad de Cuidados Intensivos Neonatales, Hospital General de Itapúa Autor/a

DOI:

https://doi.org/10.5281/zenodo.18020081

Keywords:

Ductus arteriosus, patent, Infant, premature, Acetaminophen, Treatment outcome, Patient safety, Neurodevelopmental disorders

Abstract

Introduction: Ibuprofen has historically been first-line for closing patent ductus arteriosus (PDA) in preterm infants despite known adverse effects on renal hemodynamics and gastrointestinal integrity. Paracetamol has emerged as a promising alternative, though its position as first-line therapy remains debated. This review analyzed comparative clinical efficacy, safety profile and long-term outcomes of paracetamol versus ibuprofen.

Methods: An integrative review used Whittemore and Knafl methodology. Systematic searches in PubMed, Scopus and Cochrane Central (2015–2025) used MeSH/DeCS terms. Randomized trials and observational studies comparing both drugs directly in preterm neonates (<37 weeks) were included. Evidence quality was synthesized thematically.

Results: Accumulated evidence confirms noninferiority of paracetamol, with ductal closure rates statistically comparable to ibuprofen (range 72–78%). Clinically, paracetamol showed a superior safety profile, with significantly lower incidence of oliguria, acute kidney injury and gastrointestinal bleeding, and without displacing bilirubin from albumin. No significant differences were found in neurodevelopmental outcomes at 18–24 months corrected age.

Conclusions: Paracetamol is therapeutically equipotent to ibuprofen for PDA closure but systemically gentler. Its nephroprotective capacity and hemostatic stability support preferential use in high-risk neonates, challenging current therapeutic inertia and suggesting needed updates to neonatal clinical guidelines.

References

Bagheri MM, Niknafs P, Sabsevari F, Torabi MH, Bahman Bijari B, Noroozi E, et al. Comparison of oral Acetaminophen versus Ibuprofen in premature infants with patent ductus arteriosus. Iran J Pediatr. 2016 Aug;26(4):e3975.

Nishizaki N, Matsuda A, Yoneyama T, Watanabe A, Obinata K, Shimizu T. The influence on renal function of ibuprofen treatment for patent ductus arteriosus in extremely low birthweight infants. Pediatr Int. 2020 Feb;62(2):193–9.

Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013 Nov 4;8(11):e77888.

Kumar A, Gosavi RS, Sundaram V, Oleti TP, Krishnan A, Kiran S, et al. Oral paracetamol vs oral ibuprofen in patent ductus arteriosus: A randomized, controlled, noninferiority trial. J Pediatr. 2020 Jul;222:79–84.e2.

Taslimi Taleghani N, Hamrahi B, Falahi M, Nazar E, Palizban F, Naseh A, et al. Treatment of patent ductus arteriosus in premature infants: Intravenous paracetamol or oral ibuprofen? Arch Iran Med. 2023 Jun 1;26(6):330–7.

Xiao Y, Liu H, Hu R, You Q, Zeng M, Jiang X. Efficacy and safety of paracetamol for patent ductus arteriosus closure in preterm infants: An updated systematic review and meta-analysis. Front Pediatr. 2019;7:568.

Katsaras DN, Katsaras GN, Chatziravdeli VI, Papavasileiou GN, Touloupaki M, Mitsiakos G, et al. Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022 Jul;88(7):3078–100.

El-Khuffash A, Jain A, Corcoran D, Shah PS, Hooper CW, Brown N, et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatr Res. 2014 Sep;76(3):238–44.

Luo H, He J, Xu X, Chen H, Shi J. The impact of the route of administration on the efficacy and safety of the drug therapy for patent ductus arteriosus in premature infants: a systematic review and meta-analysis. PeerJ. 2024 Jan 29;12:e16591.

Elbayiyev S, Canpolat FE, Kadıoğlu Şimşek G, Işık S, Büyüktiryaki M, Kanmaz Kutman HG. Long-term neurodevelopmental outcomes in very low birth weight infants with and without patent ductus arteriosus: A retrospective case control observational study. Child Care Health Dev. 2022 Sep;48(5):862–8.

Oncel MY, Eras Z, Uras N, Canpolat FE, Erdeve O, Oguz SS. Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. Am J Perinatol. 2017 Oct;34(12):1185–9.

Dani C, Lista G, Bianchi S, Mosca F, Schena F, Ramenghi L, et al. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. Eur J Pediatr. 2021 Mar;180(3):807–16.

Lee CC, Chan OW, Lai MY, Hsu KH, Wu TW, Lim WH, et al. Incidence and outcomes of acute kidney injury in extremely-low-birth-weight infants. PLoS One. 2017 Nov 6;12(11):e0187764.

Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: A systematic review and meta-analysis. JAMA. 2018 Mar 27;319(12):1221–38.

Terrin G, Conte F, Oncel MY, Scipione A, McNamara PJ, Simons S, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonates: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2016 Mar;101(2):F127–36.

Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013;103(3):166–9.

Höck M, Sappler M, Hammerl M, Griesmaier E, Ndayisaba JP, Schreiner C, et al. Prophylactic low-dose paracetamol for ductal closure and neurodevelopmental outcome in very preterm infants. Acta Paediatr. 2023 Aug;112(8):1706–14.

Yang B, Gao X, Ren Y, Wang Y, Zhang Q. Oral paracetamol vs. oral ibuprofen in the treatment of symptomatic patent ductus arteriosus in premature infants: A randomized controlled trial. Exp Ther Med. 2016 Oct;12(4):2531–6.

Arif M, Afridi AS, Ali F, Abrar Buneri SU, Salman M. Comparison of efficacy of oral ibuprofen versus paracetamol for PDA closure in preterm neonates. Pakistan Journal of Medical and Health Sciences. 2021 Aug 30;15(8):2529–32.

Published

2025-12-22

Issue

Section

Review Articles

How to Cite

Superior safety and equipotent efficacy of paracetamol versus ibuprofen for closure of patent ductus arteriosus: An integrative review (2015–2025). (2025). Revista UniNorte De Medicina Y Ciencias De La Salud, 14(3), 104–109. https://doi.org/10.5281/zenodo.18020081

Similar Articles

11-20 of 269

You may also start an advanced similarity search for this article.